SAN DIEGO, CA--(Marketwired - June 04, 2014) - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles.
The Company's presentation by Dr. Dennis Carlo, President and CEO, will begin at 11:00 a.m. PDT. Dr. Carlo will provide an update on the Company's specialty pharmaceutical programs including its recently filed NDA for epinephrine injection.
About LD Mirco
LD Micro is a newsletter firm that focuses on finding undervalued companies in the mirco-cap space. The conference hosts 100 companies and provides them with the opportunity to showcase to quality private and institutional investors. For more information on the conference please visit ldmicro.com.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.